CLINICAL TRIALS PROFILE FOR MAVENCLAD
✉ Email this page to a colleague
All Clinical Trials for MAVENCLAD
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03150004 ↗ | Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia | Recruiting | Medical College of Wisconsin | Phase 2 | 2017-06-14 | This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives. |
NCT03364036 ↗ | Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) | Active, not recruiting | Merck KGaA, Darmstadt, Germany | Phase 4 | 2018-05-28 | The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS). |
NCT03369665 ↗ | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) | Active, not recruiting | Merck KGaA, Darmstadt, Germany | Phase 4 | 2018-06-20 | The main purpose of the study is to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAVENCLAD
Condition Name
Clinical Trial Locations for MAVENCLAD
Trials by Country
Clinical Trial Progress for MAVENCLAD
Clinical Trial Phase
Clinical Trial Sponsors for MAVENCLAD
Sponsor Name